46
Participants
Start Date
February 1, 2023
Primary Completion Date
December 1, 2025
Study Completion Date
December 31, 2025
Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
RECRUITING
Michael E. DeBakey VA Medical Center, Houston, TX, Houston
VA Office of Research and Development
FED